欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Riviciclib_920113-02-6_产品详情
920113-02-6
  • names:

    Riviciclib

  • CAS号:

    920113-02-6

    MDL Number:
  • MF(分子式): C21H20ClNO5 MW(分子量): 401.84
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Riviciclib
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM002323-500mg 500mg ¥ 0.00 ¥ 0.00 Backorder
- +
¥ 0.00
YZM002323-250mg 250mg >97% ¥ 0.00 ¥ 0.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 920113-02-6
Inchi
InchiKey
分子式 Formula C21H20ClNO5
分子量 Molecular Weight 401.84
溶解度Solubility
性状
储藏条件 Storage conditions 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description.
Riviciclib(CAS:920113-02-6)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Riviciclib (P276-00 free base) 为有效的CDK抑制剂,抑制CDK9-cyclinT1,CDK4-cyclin D1,CDK1-cyclinB的IC50值分别为 20 nM,63 nM,79 nM
IntroductionRiviciclib (P2760 free base) is a potentcyclinependent kinase (CDK)inhibitor, which inhibitsCDK9yclinT1,CDK4yclin D1, andCDK1yclinBwithIC50s of 20 nM, 63 nM, and 79 nM, respectively[2]. Riviciclib shows antitumor activity on cisplatinesistant cells[3].
Application1
Application2
Application3
Riviciclib (P276-00 free base) 为有效的CDK抑制剂,抑制CDK9-cyclinT1,CDK4-cyclin D1,CDK1-cyclinB的IC50值分别为 20 nM,63 nM,79 nM。Riviciclib 对 Cisplatin 耐药性细胞具有抗肿瘤活性。Riviciclib (P276-00 free base) is a potentcyclin-dependent kinase (CDK)inhibitor, which inhibitsCDK9-cyclinT1,CDK4-cyclin D1, andCDK1-cyclinBwithIC50s of 20 nM, 63 nM, and 79 nM, respectively[1][2]. Riviciclib shows antitumor activity on cisplatin-resistant cells[3].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Roskoski R Jr,Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.Pharmacol Res. 2016 May;107:249-275.
【2】.Joshi KS, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6(3):918-25.
【3】.Joshi KS,et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents